INTRODUCTION
============

Cardiovascular disease (CVD) and osteoporosis are major diseases that cause marked morbidity, disability, and mortality, and a very large socioeconomic burden worldwide.^[@r01]--[@r03]^ In their review, Deaton et al noted that CVD accounts for about one-third of all deaths in the world.^[@r01]^ Another review showed that osteoporosis is responsible for fractures in about 2 million people in the United States annually.^[@r02]^ Recently, accumulating evidence shows a robust association between CVD and osteoporosis/osteoporotic fracture, which share risk factors and pathophysiologic pathways.^[@r04]--[@r09]^ Aging, menopause, and chronic inflammation may partially explain this association.^[@r06],[@r07]^ A study in Australia by Chen et al found that fracture was 1.23 times (95% CI = 1.13--1.35) as likely among women with CVD than among those without CVD.^[@r08]^ Gerber et al reported that US patients had a 1.32-fold risk of fracture (95% CI = 1.12--1.56) after myocardial infarction.^[@r09]^

In 2010, CVD was the second leading cause of death in Taiwan, accounting for 10.8% of all deaths.^[@r10]^ In a study using data from the Taiwan National Health Insurance database, Yang et al estimated that the average prevalence of osteoporosis in 1999--2001 was 11.4% in women, and 1.6% in men, aged 50 years or older.^[@r11]^ To date, most studies of the association between CVD and osteoporosis/osteoporotic fracture were limited to white populations, and little evidence is available in Taiwan. Identifying risk factors for fracture is important in preventing development of fractures and improving outcomes. In this population-based cohort study, we used claims data from the National Health Insurance program in Taiwan to investigate the association between CVD and risk of major osteoporotic fracture.

METHODS
=======

Data sources
------------

This study used claims data from the National Health Insurance program in Taiwan, which has been described in detail in previous studies.^[@r12]--[@r16]^ In brief, the National Health Research Institute in Taiwan has used insurance claims data to establish several longitudinal data files on medical services provided to inpatients and outpatients. All data files were linked with scrambled identifiers to protect patient privacy. Disease diagnoses were coded according to the International Classification of Diseases 9th Revision-Clinical Modification (ICD-9-CM). In addition, the A-code was used to define diseases, because its use predated adoption of ICD-9 coding in Taiwan.

Design
------

We used claims data covering 1 million insured persons and established 2 study groups. The CVD group included patients who received new diagnoses during 2000--2007 of coronary artery disease (ICD-9 410--414; A-code A270, A279), heart failure (ICD-9 428), cerebrovascular disease (ICD-9 430--438; A-code A290--A294, A299), or peripheral atherosclerosis (ICD-9 440--448; A-code A300). All people younger than 50 years on the day of diagnosis were excluded. For each selected CVD patient, 1 adult without medical claims for CVD was randomly selected for the non-CVD group, after frequency-matching for sex, age (every 5-year span), and index data. The index date was defined as the date of diagnosis for CVD patients and as the middle date of the same index month as their matched CVD patients for non-CVD subjects. To decrease confounding effects, subjects previously diagnosed with fracture at any site (ICD-9 800--829, E887, and A-code A470--A476, A479) before the index date were excluded from the study. Diagnosis of a major osteoporotic fracture, including fracture of the spine (ICD-9 805 and 806), hip (ICD-9 820), humerus (ICD-9 812), and forearm (ICD-9 813)/wrist (ICD-9 814), were used as the study end-point. These fracture sites have been defined by the World Health Organization fracture risk assessment tool, FRAX.^[@r17]^ Both the CVD and non-CVD groups were followed up to determine fracture incidence until a subject received a fracture diagnosis, death, withdrawal from the insurance program, loss to follow-up, or December 31, 2010.

Comorbidities potentially associated with major osteoporotic fracture before the index date were hypertension, arrhythmia, hyperlipidemia, obesity, diabetes mellitus, dementia, Parkinson's disease, depression, chronic kidney disease, osteoporosis, menopause, cancer, thyrotoxicosis, tobacco use, and alcoholism. All were diagnosed by using ICD-9 code and A-code.

Definition of exposure
----------------------

Medical therapy for osteoporosis was defined as at least 1 recorded prescription for bisphosphonate, calcitonin, estrogen, or raloxifene before the index date. Use of other bone-related medications was defined as at least 1 prescription for thiazolidinedione, proton-pump inhibitor, glucocorticoid, statin, warfarin, or heparin before the index date.

Statistical analysis
--------------------

Demographic status, comorbidities, and medications were compared between the CVD and non-CVD groups among men and women separately. The chi-square test and Student *t* test were used to compare differences between the CVD and non-CVD groups in sociodemographic characteristics, comorbidities, and medications. The incidence rate of fracture was calculated as number of fracture cases identified during follow-up divided by total person-years for each group. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs for sex-specific risk of hip fracture and major osteoporotic fracture in association with CVD. Subanalysis evaluated whether different types of CVD were associated with risk of major osteoporotic fracture. All analyses were performed using SAS software version 9.1 (SAS Institute Inc., Cary, NC, USA), and the statistical significance level was defined as a 2-sided *P* value less than 0.05.

RESULTS
=======

Baseline characteristics of the study population
------------------------------------------------

Analysis of claims data from 2000--2007 revealed 43 874 patients with CVD (CVD group) and 43 874 subjects free from disease (non-CVD group) who met the eligibility criteria. Men in the CVD group had a significantly shorter mean duration of follow-up than did men in the non-CVD group (6.03 vs 6.44 years, *P* \< 0.0001; Table [1](#tbl01){ref-type="table"}). Comorbidities and medications were more frequent in the CVD group than in the non-CVD group, with the exception of obesity, cancer, and use of bisphosphonate and raloxifene. Women in the CVD group had a significantly shorter mean duration of follow-up than did women in the non-CVD group (6.25 vs 6.64 years, *P* \< 0.0001; Table [1](#tbl01){ref-type="table"}). As with men, most comorbidities and medications were more frequent in the CVD group than in the non-CVD group, with the exception of obesity, cancer, tobacco use, alcoholism, and use of bisphosphonate and raloxifene. There was no significant difference in medical therapy for osteoporosis between the CVD group and non-CVD group in either sex (data not shown).

###### Baseline characteristics of subjects with and without cardiovascular disease

                                    Men             Women                                                      
  --------------------------------- -------- ------ -------- ------ ---------- -------- ------ -------- ------ ----------
  Age group (years)                                                                                             
   50--64                           10 017   43.3   9849     42.5   0.11       9785     47.2   9495     45.8   0.004
   65--84                           13 144   56.8   13 312   57.5              10 928   52.8   11 218   54.2    
   Mean (SD) (years)^a^             65.8     9.14   66       9.13   0.08       65       8.91   65.2     8.9    0.028
  Follow-up years, mean (SD)        6.44     2.79   6.03     3.01   \<0.0001   6.64     2.78   6.25     2.97   \<0.0001
  Comorbidities before index date                                                                              
   Hypertension                     7818     33.8   16 655   71.9   \<0.0001   8050     38.9   15 344   74.1   \<0.0001
   Arrhythmia                       1063     4.59   3747     16.2   \<0.0001   1259     6.08   3921     18.9   \<0.0001
   Hyperlipidemia                   1815     7.84   4232     18.3   \<0.0001   2539     12.3   4888     23.6   \<0.0001
   Obesity                          11       0.05   19       0.08   0.14       18       0.09   29       0.14   0.11
   Diabetes mellitus                3213     13.9   6461     27.9   \<0.0001   3233     15.6   6529     31.5   \<0.0001
   Dementia                         179      0.77   377      1.63   \<0.0001   140      0.68   292      1.41   \<0.0001
   Parkinson's disease              246      1.06   465      2.01   \<0.0001   194      0.94   358      1.73   \<0.0001
   Depression                       558      2.41   862      3.72   \<0.0001   734      3.54   1269     6.13   \<0.0001
   Chronic kidney disease           432      1.87   972      4.2    \<0.0001   252      1.22   772      3.73   \<0.0001
   Osteoporosis                     390      1.68   628      2.71   \<0.0001   2804     13.5   3850     18.6   \<0.0001
   Menopause                        ---      ---    ---      ---    ---        3905     18.9   4992     24.1   \<0.0001
   Cancers                          894      3.86   785      3.39   0.007      829      4      719      3.47   0.004
   Thyrotoxicosis                   94       0.41   123      0.53   0.049      267      1.29   382      1.84   \<0.0001
   Tobacco use                      39       0.17   80       0.35   0.0002     4        0.02   6        0.03   0.53
   Alcoholism                       55       0.24   107      0.46   \<0.0001   3        0.01   6        0.03   0.32
  Ever use of medications                                                                                      
   Thiazolidinedione                260      1.12   564      2.44   \<0.0001   216      1.04   623      3.01   \<0.0001
   Proton-pump inhibitor            999      4.31   1746     7.54   \<0.0001   569      2.75   1087     5.25   \<0.0001
   Glucocorticoid                   3509     37.6   19 652   53.1   \<0.0001   2043     35.4   18 670   52.4   \<0.0001
   Statin                           1031     4.45   3006     13     \<0.0001   1533     7.4    3407     16.5   \<0.0001
   Warfarin                         87       0.38   551      2.38   \<0.0001   55       0.27   374      1.81   \<0.0001
   Heparin                          209      0.9    1454     6.28   \<0.0001   166      0.8    718      3.47   \<0.0001
   Bisphosphonate                   13       0.06   17       0.07   0.47       109      0.53   119      0.57   0.51
   Calcitonin                       30       0.13   62       0.27   0.0008     153      0.74   224      1.08   0.0002
   Estrogen                         ---      ---    ---      ---    ---        1652     7.98   2051     9.9    \<0.0001
   Raloxifene                       1        0      0        0      0.99       25       0.12   25       0.12   0.99

The chi-square test and ^a^*t*-test were used to compare subjects with and without cardiovascular disease.

Association between CVD and hip fracture
----------------------------------------

Table [2](#tbl02){ref-type="table"} shows the sex-specific risk of hip fracture by duration of follow-up for the CVD and non-CVD groups. The incidence of hip fracture was highest among women with CVD (4.27 per 1000 person-years), followed by women without CVD, men with CVD, and men without CVD (1.96 per 1000 person-years). Multivariate Cox regression analysis revealed that the HR for hip fracture associated with CVD was not significant (HR, 1.02; 95% CI = 0.92, 1.13).

###### Incidence and hazard ratios (HRs) for hip fracture among subjects with and without cardiovascular disease (CVD), by sex and duration of follow-up

  -------------------------------------------------------------------------------------------------------------------------
                    Non-CVD   CVD       Crude HR\   Adjusted HR\                                        
                                        (95% CI)    (95% CI)                                            
  ----------------- --------- --------- ----------- -------------- --------- ------ ------------------- -------------------
  Men               298       151 808   1.96        399            142 873   2.79   1.43 (1.23, 1.66)   0.93 (0.79, 1.10)

  Follow-up years                                                                                        

  ≤1                32        22 793    1.40        46             22 186    2.07   1.47 (0.94, 2.32)   0.77 (0.45, 1.32)

  \>1               266       129 016   2.06        353            120 686   2.92   1.42 (1.21, 1.67)   0.95 (0.79, 1.13)

                                                                                                        

  Women             422       145 104   2.91        591            138 555   4.27   1.47 (1.30, 1.67)   1.11 (0.97, 1.27)

  Follow-up years                                                                                        

  ≤1                36        20 528    1.75        76             20 146    3.77   2.15 (1.45, 3.20)   0.96 (0.63, 1.45)

  \>1               386       124 577   3.10        515            118 409   4.35   1.41 (1.24, 1.61)   1.13 (0.98, 1.30)

                                                                                                        

  Overall           720       296 913   2.42        990            281 428   3.52   1.46 (1.32, 1.60)   1.02 (0.92, 1.13)

  Follow-up years                                                                                        

  ≤1                68        43 320    1.57        122            42 333    2.88   1.84 (1.36, 2.47)   0.87 (0.63, 1.21)

  \>1               652       253 592   2.57        868            239 096   3.63   1.42 (1.28, 1.57)   1.03 (0.93, 1.16)
  -------------------------------------------------------------------------------------------------------------------------

Adjusted HR in men: adjusted for age, hypertension, arrhythmia, diabetes mellitus, dementia, Parkinson's disease, depression, chronic kidney disease, osteoporosis, alcoholism, proton-pump inhibitor, glucocorticoid, and calcitonin.

Adjusted HR in women: adjusted for age, hypertension, arrhythmia, hyperlipidemia, diabetes mellitus, dementia, Parkinson's disease, chronic kidney disease, osteoporosis, menopause, thiazolidinedione, glucocorticoid, bisphosphonate, calcitonin, estrogen, and raloxifene.

Adjusted overall HR: adjusted for age, diabetes mellitus, hyperlipidemia, Parkinson's disease, osteoporosis, glucocorticoid, bisphosphonate, calcitonin, and estrogen.

^a^Incidence rate: per 1000 person-years.

Association between CVD and major osteoporotic fractures
--------------------------------------------------------

Table [3](#tbl03){ref-type="table"} shows the sex-specific risk of major osteoporotic fracture by duration of follow-up among adults with and without CVD. The incidence of fracture was highest among women with CVD (21.5 per 1000 person-years), followed by women without CVD, men with CVD, and men without CVD (7.02 per 1000 person-years). Multivariate Cox regression analysis revealed that the HR for major osteoporotic fracture associated with CVD was 1.16 (95% CI 1.10, 1.22). The sex-specific HRs were similar for men and women (HR, 1.24 vs 1.18). The risk of fracture declined slightly after 1 year of follow-up.

###### Incidence and hazard ratios (HRs) for major osteoporotic fractures among subjects with and without cardiovascular disease (CVD), by sex and duration of follow-up

  -------------------------------------------------------------------------------------------------------------------------
                    Non-CVD   CVD       Crude HR\   Adjusted HR\                                        
                                        (95% CI)    (95% CI)                                            
  ----------------- --------- --------- ----------- -------------- --------- ------ ------------------- -------------------
  Men               1047      149 200   7.02        1276           139 562   9.14   1.31 (1.20, 1.42)   1.24 (1.13, 1.36)

  Follow-up years                                                                                        

  ≤1                128       22 747    5.63        195            22 109    8.82   1.57 (1.25, 1.96)   1.47 (1.15, 1.88)

  \>1               919       126 453   7.27        1081           117 453   9.20   1.27 (1.16, 1.39)   1.21 (1.09, 1.33)

                                                                                                        

  Women             2324      137 578   16.9        2786           129 484   21.5   1.28 (1.21, 1.35)   1.18 (1.11, 1.25)

  Follow-up years                                                                                        

  ≤1                296       20 404    14.5        412            19 972    20.6   1.42 (1.23, 1.65)   1.32 (1.12, 1.55)

  \>1               2028      117 174   17.3        2374           109 512   21.7   1.26 (1.18, 1.33)   1.16 (1.08, 1.23)

                                                                                                        

  Overall           3371      286 778   11.8        4062           269 047   15.1   1.29 (1.23, 1.35)   1.16 (1.10, 1.22)

  Follow-up years                                                                                        

  ≤1                424       43 152    9.83        607            42 081    14.4   1.47 (1.30, 1.66)   1.33 (1.16, 1.52)

  \>1               2947      243 627   12.1        3455           226 965   15.2   1.26 (1.20, 1.32)   1.14 (1.08, 1.20)
  -------------------------------------------------------------------------------------------------------------------------

Adjusted HR in men: adjusted for age, hypertension, arrhythmia, diabetes mellitus, dementia, Parkinson's disease, depression, chronic kidney disease, osteoporosis, alcoholism, proton-pump inhibitor, glucocorticoid, and calcitonin.

Adjusted HR in women: adjusted for age, hypertension, arrhythmia, hyperlipidemia, diabetes mellitus, dementia, Parkinson's disease, chronic kidney disease, osteoporosis, menopause, thiazolidinedione, glucocorticoid, bisphosphonate, calcitonin, estrogen, and raloxifene.

Adjusted overall HR: adjusted for age, diabetes mellitus, hyperlipidemia, Parkinson's disease, osteoporosis, glucocorticoid, bisphosphonate, calcitonin, and estrogen.

^a^Incidence rate: per 1000 person-years.

Subanalysis of the association between type of CVD and major osteoporotic fracture
----------------------------------------------------------------------------------

The association between type of CVD and risk of major osteoporotic fracture was also analyzed (Table [4](#tbl04){ref-type="table"}). As compared with the non-CVD group, the adjusted HR of major osteoporotic fracture was highest among patients with cerebrovascular disease (HR 1.31, 95% CI 1.23, 1.39), followed by those with heart failure (1.18; 1.11, 1.27), peripheral atherosclerosis (1.12; 1.04, 1.20), and coronary artery disease (1.07; 1.01, 1.12).

###### Hazard ratios (HRs) and 95% CIs for major osteoporotic fracture associated with 4 types of cardiovascular disease (CVD)

                                Crude HR (95% CI)   Adjusted HR (95% CI)
  ----------------------------- ------------------- ----------------------
  Men                                                
   Non-CVD (reference)          1.00 (Reference)    1.00 (Reference)
   Coronary artery disease      1.09 (1.00, 1.18)   1.05 (0.96, 1.15)
   Heart failure                1.58 (1.41, 1.78)   1.29 (1.14, 1.45)
   Cerebrovascular disease      1.71 (1.55, 1.89)   1.47 (1.33, 1.63)
   Peripheral atherosclerosis   1.32 (1.16, 1.50)   1.21 (1.06, 1.37)
  Women                                              
   Non-CVD (reference)          1.00 (Reference)    1.00 (Reference)
   Coronary artery disease      1.16 (1.10, 1.23)   1.12 (1.05, 1.18)
   Heart failure                1.45 (1.34, 1.58)   1.12 (1.03, 1.22)
   Cerebrovascular disease      1.67 (1.55, 1.80)   1.32 (1.23, 1.43)
   Peripheral atherosclerosis   1.16 (1.06, 1.26)   1.10 (1.01, 1.20)
  Overall                                            
   Non-CVD (reference)          1.00 (Reference)    1.00 (Reference)
   Coronary artery disease      1.15 (1.10, 1.20)   1.07 (1.01, 1.12)
   Heart failure                1.50 (1.40, 1.60)   1.18 (1.11, 1.27)
   Cerebrovascular disease      1.57 (1.48, 1.66)   1.31 (1.23, 1.39)
   Peripheral atherosclerosis   1.23 (1.15, 1.32)   1.12 (1.04, 1.20)

Adjusted HR in men: adjusted for age, hypertension, arrhythmia, diabetes mellitus, dementia, Parkinson's disease, depression, chronic kidney disease, osteoporosis, alcoholism, proton-pump inhibitor, glucocorticoid, and calcitonin.

Adjusted HR in women: adjusted for age, hypertension, arrhythmia, hyperlipidemia, diabetes mellitus, dementia, Parkinson's disease, chronic kidney disease, osteoporosis, menopause, thiazolidinedione, glucocorticoid, bisphosphonate, calcitonin, estrogen, and raloxifene.

Adjusted overall HR: adjusted for age, diabetes mellitus, hyperlipidemia, Parkinson's disease, osteoporosis, glucocorticoid, bisphosphonate, calcitonin, and estrogen.

DISCUSSION
==========

Although this study is not novel, it is to our knowledge the first population-based cohort study to examine the association between CVD and risk of major osteoporotic fracture in Taiwan. We selected only adults aged 50 years or older, and the prevalences of most comorbidities and medications were therefore greater among the CVD group than among the non-CVD group. The incidence of major osteoporotic fracture among women was more than 2-fold that among men, regardless of CVD status. Our finding of a risk of major osteoporotic fracture was somewhat comparable to the results of previous studies (risk rates, 1.2 to 1.5).^[@r07]--[@r09]^ The present study found that the overall risk of fracture in the CVD group was approximately 1.2-fold that of the non-CVD group. However, there were variations in men and women with regard to duration of follow-up and interaction between comorbidities.

Additional analysis by CVD type showed that cerebrovascular disease (HR 1.31), heart failure (HR 1.18), peripheral atherosclerosis group (HR 1.12), and coronary artery disease (HR 1.07) were substantially associated with increased risk of major osteoporotic fracture. Two studies by Sennerby et al showed that Swedish patients with cerebrovascular disease had higher fracture risk (OR = 2.76 and HR = 5.09),^[@r04],[@r05]^ and our findings are similar. The authors suggested that the increased likelihood of falling after cerebrovascular disease partially explained this trend.^[@r04],[@r05]^

Variation in fracture risk during follow-up is important in preventive care. Though the absolute incidence rate of major osteoporotic fracture was higher after 1 year of follow-up, the hazard was lower during subsequent follow-up. In contrast, Sennerby et al found a higher risk of hip fracture within the first year after a CVD diagnosis in Sweden.^[@r04],[@r05]^ In the present study, the absolute incidence rate of hip fracture was higher among the CVD group, but the HR was not statistically significant (HR 1.02, 95% CI 0.92, 1.13). Although the time-course effect differed between previous studies and the present study, we believe that clinicians should be mindful of the risk of major osteoporotic fracture even at 1 year after a CVD diagnosis, as risk did not substantially vary during the follow-up period.

Some limitations should be addressed. First, because claims data were used, some CVD diagnoses might not fulfill all criteria for each disease. Also, instances of fracture at hip or major skeletal sites could not be diagnosed as fragility fracture. This limitation may have led to underestimation of fracture risk. Second, because claims data did not provide information on bone mineral density (BMD), we were unable to evaluate fracture risk in relation to presence of osteoporosis, osteopenia, or normal BMD. Therefore, we were unable to examine the relation between CVD and BMD. Third, although there was no record of body mass index (BMI) in the claims data, we were able to include information on obesity (ie, ICD-9 278.00 and 278.01 and A-code A183) as a comorbidity in the analysis.

Conclusion
----------

After careful adjustment for covariates and consideration of duration of follow-up, CVD was associated with increased risk of major osteoporotic fracture in both sexes, although the incidence of such fractures was higher among women than among men.
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